{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:25:36Z","timestamp":1767979536361,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.aohep.2021.100566","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:19:25Z","timestamp":1634890765000},"page":"100566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection"],"prefix":"10.1016","volume":"27","author":[{"given":"Tomoaki","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyasu","family":"Karino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Hige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Suii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2021.100566_bib0001","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0002","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cir306","article-title":"All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population","volume":"53","author":"El-Kamary","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.aohep.2021.100566_bib0003","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10620-011-1621-2","article-title":"Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis","volume":"56","author":"Velosa","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2021.100566_bib0004","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jgh.13589","article-title":"Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis","volume":"32","author":"Tada","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2021.100566_bib0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2021.100566_bib0006","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.aohep.2021.100566_bib0007","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","article-title":"Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders","volume":"55","author":"Chayama","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2021.100566_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/jgh.15280","article-title":"Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients","volume":"36","author":"Nakajima","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2021.100566_bib0009","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.aohep.2021.100566_bib0010","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hepr.13246","article-title":"Real-world efficacy and safety of sofosbuvir\u00a0+\u00a0ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group","author":"Akahane","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2021.100566_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0013","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","article-title":"Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis","volume":"62","author":"Kumada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0014","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0016","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/ggi.13118","volume":"17","author":"Ouchi","year":"2017","journal-title":"Geriatr Gerontol Int"},{"issue":"6","key":"10.1016\/j.aohep.2021.100566_bib0017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2021.100566_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324525","article-title":"Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale","volume":"54","author":"Tanaka","year":"2011","journal-title":"Intervirology"},{"key":"10.1016\/j.aohep.2021.100566_bib0019","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00535-011-0403-0","article-title":"The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan","volume":"46","author":"Oze","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100566_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000089372","article-title":"Efficacy of interferon therapy in elderly patients with chronic hepatitis C","volume":"49","author":"Koyama","year":"2006","journal-title":"Intervirology"},{"key":"10.1016\/j.aohep.2021.100566_bib0021","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10620-019-05886-y","article-title":"Noninvasive measurements predict liver fibrosis well in hepatitis C virus patients after direct-acting antiviral therapy","volume":"65","author":"Huang","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2021.100566_bib0022","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jvh.13280","article-title":"Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-results from the German Hepatitis C-Registry","volume":"27","author":"Knop","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2021.100566_bib0023","doi-asserted-by":"crossref","unstructured":"Bachofner JA, Valli PV, Kr\u00f6ger A, Bergamin I, K\u00fcnzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, M\u00fcllhaupt B, Terziroli Beretta-Piccoli B, Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. C.Liver Int. 2017; 37:369-376. doi: 10.1111\/liv.13256.","DOI":"10.1111\/liv.13256"},{"key":"10.1016\/j.aohep.2021.100566_bib0024","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12876-019-0973-5","article-title":"Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents","volume":"19","author":"Hsu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100566_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100566_bib0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/liv.13659","article-title":"The impact of treatment of hepatitis C with DAAs on the occurrence of HCC","volume":"38","author":"Roche","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2021.100566_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21173","article-title":"Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C in the era of direct-acting antiviral agents","volume":"3","author":"Chen","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.aohep.2021.100566_bib0028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2021.100566_bib0029","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"issue":"3","key":"10.1016\/j.aohep.2021.100566_bib0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4318\/tjg.2011.0213","article-title":"AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"2","author":"G\u00fczelbulut","year":"2011","journal-title":"Turk J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2021.100566_bib0031","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4254\/wjh.v9.i6.310","article-title":"Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C","volume":"28","author":"Chindamo","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.aohep.2021.100566_bib0032","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2021.100566_bib0033","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/hepr.13296","article-title":"Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index","volume":"49","author":"Seko","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2021.100566_bib0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","article-title":"Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial","volume":"54","author":"Takehara","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100566_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jceh.2018.02.009","article-title":"Results of sofosbuvir plus ribavirin in patients with hepatitis C related decompensated cirrhosis","volume":"9","author":"Naveen","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.aohep.2021.100566_bib0036","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2021.100566_bib0037","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:43:09Z","timestamp":1761648189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268121002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1665268121002659"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100566","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100566"}}